This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CorMedix (CRMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Upgraded to Buy: Here's Why
by Zacks Equity Research
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Momentum Investors Will Love CorMedix (CRMD)
by Zacks Equity Research
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Jumps: Stock Rises 9.8%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Jumps: Stock Rises 7.5%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for April 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 22nd
Will CorMedix Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor CorMedix
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
by Zacks Equity Research
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
CorMedix (CRMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of -9.09% and -73.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.